As PDRN (polydeoxyribonucleotide) products enter mainstream aesthetic practice, one of the most common questions practitioners ask is deceptively simple: for a given patient, should I use PDRN or a HA skin booster? The question is deceptive because it implies a binary choice where the more useful clinical framing is a spectrum — with most patients sitting somewhere in the middle where both could offer benefit, and the skill lying in knowing which mechanism addresses their dominant concern more directly.

Most practitioners know that hyaluronic acid is the active ingredient in skin booster treatments. Fewer know that not all HA is clinically equivalent — and that the molecular weight of the HA in a product is one of the most important determinants of how that product will behave in tissue, what biological effects it will produce, and which patient profile and treatment goal it is best suited to.

Skin booster treatments have one of the highest patient satisfaction rates in aesthetic medicine — when the right patient is treated, with the right product, and with appropriate outcome expectations established at consultation. They also have one of the most predictable routes to patient dissatisfaction: treating a patient whose concern is structural volume loss with a treatment that addresses skin quality, or promising 'glowing, radiant skin' to a patient whose primary visible concern is a fat hernation or significant volume deficit that biorevitalisation cannot address.

Skin quality treatment of the periorbital area is one of the highest-value aesthetic services a practitioner can offer — patients who see genuine improvement in the appearance of tiredness and dark circles without the risks of tear trough filler are reliably among the most satisfied in any practice. But delivering that result requires a precise understanding of what the periorbital skin needs, what it cannot tolerate, and which product categories are clinically appropriate for this uniquely challenging zone.

The most sophisticated aesthetic practitioners do not offer standalone treatments — they design treatment plans. And the most consistently impressive results in non-surgical facial rejuvenation come not from any single treatment but from coordinated protocols that address multiple dimensions of the ageing face simultaneously: skin quality, skin hydration, dynamic movement, structural volume, and collagen architecture.

Skin booster technique is where the product's clinical potential is either realised or wasted. Unlike dermal filler placement — where anatomical precision at specific landmark points drives the outcome — skin booster results depend on consistent technique executed across a broad treatment zone. A correctly formulated product administered with inconsistent depth, incorrect volume per point, or inadequate zone coverage will produce inconsistent results regardless of how well the consultation and patient selection were conducted.

Skin boosters and dermal fillers are both injectable HA products. They are often displayed side by side in clinic price lists, administered by the same practitioners, and occasionally confused by patients — and even, more problematically, by practitioners — as interchangeable treatments. They are not.

Skin boosters have become one of the most searched and most requested injectable treatments in UK and European aesthetics — and one of the most misunderstood. The term is used loosely across the industry to describe a broad category of hydration-focused injectables that range from simple low-viscosity hyaluronic acid preparations to complex formulations combining HA with polynucleotides, amino acids, and growth factors. The clinical results, techniques, and patient selection criteria differ significantly across this spectrum.